[Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
Vinorelbine is a new semisynthetic vinca alkaloid with significantly less neurotoxicity than other vinca alkaloids. It was recently approved by the Ministry of Health and Welfare in Japan for the treatment of non-small-cell lung cancer. Vinorelbine is active in metastatic breast cancer with a first time response rate of 40% to 52%. High response rates were observed with combination chemotherapies of vinorelbine and other active agents for breast cancer. In non-small-cell lung cancer, four randomized phase III trials of vinorelbine demonstrated that vinorelbine alone, or combination chemotherapy of vinorelbine with cisplatin, improved survival more than best supportive care or cisplatin plus vindesine, respectively. There is a high level of evidence that vinorelbine is an effective agent for the treatment of non-small-cell lung cancer.